Results
14
Smaller, under-the-radar companies, backed by insider buying, presenting a compelling opportunity for investors seeking undervalued gems.
14 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
HLS | AU$1.47 | 2.8% | -45.6% | AU$1.1b | AU$1.41 | PB1x | E91.1% | 0% | Healthcare | ||
CDA | AU$12.86 | 4.3% | 61.6% | AU$2.3b | AU$11.42 | PE31.1x | E16.2% | 1.6% | Tech | ||
REP | AU$0.67 | 5.6% | -5.7% | AU$338.4m | n/a | PB1.4x | E112.0% | 8.1% | Real Estate | ||
DDR | AU$10.36 | 0.3% | 23.3% | AU$1.9b | AU$10.79 | PE22.8x | E7.8% | 4.3% | Tech | ||
APE | AU$10.59 | 3.9% | -25.2% | AU$2.7b | AU$11.96 | PE9.7x | E-0.7% | 7.0% | Retail | ||
CYG | AU$1.42 | 1.4% | 37.2% | AU$165.8m | AU$2.00 | PE297.7x | E82.3% | 2.5% | Capital Goods | ||
ELD | AU$9.20 | 1.3% | 42.6% | AU$1.5b | AU$8.83 | PE22.9x | E22.8% | 3.9% | Food, Beverage & Tobacco | ||
NEU | AU$15.32 | -3.9% | 23.8% | AU$2.0b | AU$26.54 | PE12.5x | E-10.1% | n/a | Pharmaceuticals & Biotech | ||
DRR | AU$3.68 | -3.7% | -19.7% | AU$2.0b | AU$4.49 | PE11.6x | E-8.1% | 8.6% | Materials | ||
MFF | AU$3.82 | 1.1% | 32.2% | AU$2.2b | n/a | PE4.9x | n/a | 3.7% | Diversified Financials | ||
KLS | AU$5.17 | 2.8% | -22.0% | AU$1.4b | AU$7.04 | PE47.1x | E25.5% | 3.4% | Transportation | ||
ACF | AU$1.09 | 1.9% | 23.2% | AU$322.5m | AU$1.36 | PE13x | E18.6% | 5.2% | Capital Goods | ||
PWR | AU$1.78 | 2.3% | -31.8% | AU$306.2m | AU$2.21 | PE6.4x | E-3.6% | 9.6% | Retail | ||
NWH | AU$3.50 | 9.4% | 26.8% | AU$1.6b | AU$3.78 | PE15.2x | E9.6% | 4.4% | Capital Goods |